Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.71 USD

96.71
526,084

-0.09 (-0.09%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $96.71 0.00 (0.00%) 5:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks News

Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays

Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.

Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Down

Impressive performance by the Home Health and Hospice segments drove Amedisys' (AMED) revenues in the first quarter.

Amedisys (AMED) Q1 Earnings Top Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 10.81% and 2.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Amedisys (AMED) Stock For Now

Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.

Why Is Amedisys (AMED) Up 13.2% Since Last Earnings Report?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Strong Sell Stocks for March 9th

AGESY, AMED, and APAM have been added to the Zacks Rank #5 (Strong Sell) List on March 9, 2022.

New Strong Sell Stocks for March 4th

AMED, CACC, and EXPO have been added to the Zacks Rank #5 (Strong Sell) List on March 4, 2022

Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline

Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.

Amedisys (AMED) Beats Q4 Earnings and Revenue Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 0.86% and 0.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics (DGX) Lags Q4 Earnings Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of -0.60% and 0.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for December 29th

B, FPI, CGNX, AMED, and FSUGY have been added to the Zacks Rank #5 (Strong Sell) List on December 29, 2021.

New Strong Sell Stocks for December 27th

TXRH, VIOT, WBK, AMED and CGNX have been added to the Zacks Rank #5 (Strong Sell) List on December 27, 2021

Why Is Amedisys (AMED) Down 22.9% Since Last Earnings Report?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Strong Sell Stocks for December 2nd

AMED, LGIH, SWK, TCMD, and HEINY have been added to the Zacks Rank #5 (Strong Sell) List on December 2, 2021.

New Strong Sell Stocks for November 26th

COLD, ENR, KSU, FSTR, and AMED have been added to the Zacks Rank #5 (Strong Sell) List on November 26, 2021.

New Strong Sell Stocks for November 19th

AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.

New Strong Sell Stocks for November 5th

BLMN, AMED, HL, LGIH, and PLMR have been added to the Zacks Rank #5 (Strong Sell) List on November 5, 2021.

Amedisys (AMED) Tops Q3 Earnings Estimates, Slashes '21 View

Amedisys (AMED) reports better-than-expected earnings for the third quarter on strong growth in the Home Health segment.

Amedisys (AMED) Beats Q3 Earnings Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 12.50% and -2.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Amedisys (AMED) to Report a Decline in Earnings: What to Look Out for

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LHC Group (LHCG) Finalizes Home Health & Hospice Buyout Deals

LHC Group (LHCG) to expand in Virginia Beach with the completion of the previously announced acquisition agreements with two providers, one in home health and the other in hospice.

EHC or AMED: Which Is the Better Value Stock Right Now?

EHC vs. AMED: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to LHC Group (LHCG) Stock Now

LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.

EHC or AMED: Which Is the Better Value Stock Right Now?

EHC vs. AMED: Which Stock Is the Better Value Option?

Amedisys (AMED) Down 6.5% Since Last Earnings Report: Can It Rebound?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.